Immuron Limited (NASDAQ: IMRN)
$2.62
-0.0600 ( -2.24% ) 5.4K
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Market Data
Open
$2.62
Previous close
$2.68
Volume
5.4K
Market cap
$14.88M
Day range
$2.58 - $2.68
52 week range
$1.48 - $5.96
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 17 | Oct 04, 2023 |
6-k | Quarterly Reports | 25 | Sep 28, 2023 |
20-f | Annual reports | 136 | Sep 28, 2023 |
6-k | Quarterly Reports | 6 | Sep 13, 2023 |
6-k | Quarterly Reports | 19 | Sep 11, 2023 |
6-k | Quarterly Reports | 5 | Aug 30, 2023 |
6-k | Quarterly Reports | 6 | Aug 14, 2023 |
6-k | Quarterly Reports | 6 | Aug 09, 2023 |
6-k | Quarterly Reports | 5 | Jul 25, 2023 |
6-k | Quarterly Reports | 21 | Jul 24, 2023 |